troglitazone has been researched along with Heart Defects, Congenital in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Heart Defects, Congenital: Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There is evidence that one of the key type 2 diabetes (T2D) loci identified by GWAS exerts its influence early on in life through its impact on pediatric BMI." | 1.38 | Expression analyses of the genes harbored by the type 2 diabetes and pediatric BMI associated locus on 10q23. ( Aziz, AR; Deliard, S; Grant, SF; Zhao, J, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, J | 1 |
| Deliard, S | 1 |
| Aziz, AR | 1 |
| Grant, SF | 1 |
1 other study available for troglitazone and Heart Defects, Congenital
| Article | Year |
|---|---|
Expression analyses of the genes harbored by the type 2 diabetes and pediatric BMI associated locus on 10q23.
Topics: Adipocytes; Adipogenesis; Arrhythmias, Cardiac; Body Mass Index; Cell Line; Chromans; Chromosomes, H | 2012 |